final result was corrected for dilution. Fibrinogen results were reported in mg/dL (as specified by the American Association of Blood Banking) for donor plasma or total mg (fibrinogen mg/dL multiplied by volume).
Student's paired t-test was used for analysis, with P Ͻ0.05 determined to be statistically significant.
The mean total contents (total volume ϫ fibrinogen/ factor VIII concentration) of factor VIII and fibrinogen in the CSS-generated Cryo were 216 units and 231 mg, respectively, which represents recoveries (total Cryo/ total donor plasma) of 47% and 29%, respectively. Quality-control assays over the previous 15 months of the traditionally prepared Cryo material from SMFBC yielded an average factor VIII concentration of 128 units per average volume (15.0 mL). Mean Cryo fibrinogen contents were 100 -350 mg [3] . Thus CSS-generated Cryo material was more than twice as concentrated in factor VIII (16.9 units/mL) than conventional preparations (8.5 units/mL) ( Table 1) .
We conclude that CSS generated higher concentrations and yields of factor VIII and fibrinogen than did conventional preparations. This CSS process is highly automated and takes ϳ1 h to complete the freeze-thaw cycles, markedly less than traditional blood bank methods. The CSS method facilitates rapid preparation of Cryo for either immediate clinical use or long-term storage. The Sysmex CA-6000 automated coagulation analyzer (Dade International) is a new random access instrument that is capable of performing 20 clot-based and chromogenic assays. The purpose of this study is to determine whether the CA-6000 demonstrates performance characteristics for prothrombin time (PT), derived fibrinogen (DF), activated partial thromboplastin times (aPTT), fibrinogen (FBG), thrombin time (TT), factors VII (FVII) and VIII (FVIII) activity, antithrombin (AT), and plasminogen (PLG) similar to an established coagulation analyzer, the MLA 1000C (Medical Laboratory Automation).
Summary Evaluation of the
Samples were drawn into 32 g/L sodium citrate tubes (Becton Dickinson) and centrifuged at 1300g for 10 min before analysis or freezing. Fresh and frozen (at Ϫ70°C, then quick-thawed with a 37°C waterbath before analysis) plasma samples were compared contemporaneously on the CA-6000 and MLA 1000C with the same reagents (Dade, except for TT noted below). Specimens tested within normal limits by the clinical laboratory served as normal samples but were not used to determine reference intervals. Abnormal samples were identified by documented evidence of oral anticoagulant, heparin, or fibrinolytic therapy, and (or) history of liver disease, hemophilia A, or other acquired coagulopathies to include trauma and disseminated intravascular coagulation.
Unless otherwise indicated, the principle and detail of test methods are described by Sirridge [1] . Below are the reagents used for each individual assay:
PT: Two separate thromboplastin reagents were used, Thromboplastin Cϩ (TPC) containing acetone-dehydrated rabbit brain thromboplastin, and Innovin (INN), prepared from recombinant human tissue factor and synthetic phospholipids. These reagents are moderately and highly sensitive as indicated by their International Sensitivity Index (ISI) values of 1.94 and 1.02 respectively.
DF: The DF calibrator was determined with assayed reference material (FACT, George King Biomedical) and run according to each instrument operator's manual for both PT reagent sources. This method of FBG determination is a mathematical extrapolation based on clot formation kinetics analyzed concurrently with every PT assay.
aPTT: Testing was performed with Actin FSL containing ellagic acid and purified soy and rabbit brain phosphatides, and calcium chloride.
FBG: An assay based on the modified Clauss technique [2] involved use of commercially prepared thrombin containing ϳ100 NIH units/mL. Test plasma was diluted in a buffered saline solution before analysis. A single calibration curve was determined on each respective device with assayed material (George King Biomedical).
TT: The assay was performed with commercially prepared dilute thrombin (Sigma Diagnostics) containing ϳ3-4 NIH units/mL. For the CA-6000, the thrombin is heated to 37°C before addition to test plasma. The MLA 1000C method requires addition of room temperature thrombin for this assay.
AT: Exogenous bovine thrombin and heparin are added to test plasma to form a thrombin-heparin-AT complex. The residual thrombin not bound then hydrolyzes the p-nitroalanine substrate to produce a yellow color, which is read at 405 nm. The intensity of color produced is inversely proportional to the AT present. A single calibration curve was performed at the onset and used for the duration of sample testing. PLG: This method is based on the addition of streptokinase to test plasma, which forms a complex with test plasma PLG to hydrolyze the p-nitroalanine substrate, producing a yellow color that is read at 405 nm. The intensity of color produced is proportional to PLG present. A single calibration curve was performed at the onset and used for the duration of sample testing. FVII: Testing was performed with immunodepleted FVII-deficient plasma substrate by using the PT with Innovin reagent only. The calibrator, Factor Assay Reference Plasma (Dade), was assayed before each test run with a seven-point curve.
FVIII: Testing was performed with immunodepleted FVIII-deficient plasma substrate by using the aPTT test with Actin FSL. The calibrator, Factor Assay Reference Plasma (Dade), was assayed in duplicate before each test run with a seven-point curve.
All assays requiring calibrator or patient dilutions were automatically prepared by the respective devices.
Imprecision analysis: Designated quality-control material was assayed in quadruplicate, twice daily for 3 consecutive days for all test variables. Three concentrations of controls ranging from normal to high abnormal were used for PT-TPC, DF-TPC, PT-INN, DF-INN, and aPTT assays. All other assays involved two concentrations of controls, normal and abnormal. All samples were tested in duplicate. Replicate values must match within 10% to be accepted into analysis. Any samples that failed replicate precision were repeated on both devices.
Statistical analysis: Calculations were performed by linear regression analysis with an R 2 Ͼ0.95 predetermined as an acceptable correlation. Imprecision studies are expressed by CVs (for control data) and R 2 values for replicate samples.
There was excellent correlation between the CA-6000 and the MLA 1000C for all test variables except TT (Table  1) . TT showed a significant difference (P Ͻ0.05) between the two devices despite use of the same reagent. TT on the MLA showed a lower mean prolongation than did the CA-6000 for patients with low FBG or liver disease or treated with low-dose heparin (not shown) [3] . The imprecision was similar between the two devices. The replicate testing data (all tests had an R 2 Ն0.96) indicate that single-well testing could be used to reduce reagent and consumable usage.
The CA-6000 demonstrates operational characteristics similar to another automated coagulation analyzer, the MLA 1000C. However, the reagent carousel on the CA-6000 facilitates the performance of multiple assays con- After approval by our Institutional Review Board, we obtained consent from and enrolled 40 consecutive patients. All patients had documented stabilization of their INR, and patients who had been taking coumadin Ͻ7 days were excluded. Whole-blood fingerstick samples were acquired by a single nurse practitioner (R.H.) and tested on the Coumatrak PT monitor (Boehringer Mannheim). Samples were then drawn from the patients by antecubital phlebotomy with a 20-gauge butterfly needle and syringe. The peripherally drawn whole blood was immediately (within 15 s of phlebotomy) tested on the Coumatrak and CoaguChek Plus (Boehringer Mannheim) monitors. The residual blood was then anticoagulated by placing into 32 g/L sodium citrate-containing tubes (Becton Dickinson), and the citrated whole blood was immediately tested on the Thrombolytic Assessment System (TAS; Cardiovascular Diagnostics). The citrated samples were then centrifuged at 1800g for 15 min, and the plasma obtained was analyzed by the clinical laboratory PT method within 2 h of collection. To avoid cold activation of factor VII, citrated samples were kept at room temperature until assay.
Both Coumatrak and CoaguChek Plus are based on the same method principle, utilizing a test cartridge containing rabbit brain thromboplastin, stabilizers, and preservatives. A single drop of whole blood (noncitrated) is added to the test cartridge inserted into the monitor. The blood travels by capillary action, mixes with thromboplastin in the reagent chamber, and continues to flow along a reaction track until a clot is formed. An optical laser monitors this blood flow, and the resulting time to clot formation is displayed in seconds; PT ratio and INR are also reported. 
